How does the EU drug development landscape differ from the US ?
How does the EU drug development landscape differ from the US?
What's Inside the Q&A:
Regulatory Structure Comparison
Breakdown of how drug approvals are managed in the US (FDA) versus the EU (EMA and national agencies).
Review Process & Timelines
Key differences in how reviews are conducted – continuous FDA reviews vs. EMA’s milestone-based process.
Harmonization vs. Fragmentation
How EU-wide standards still require navigation of country-specific requirements and expectations.
Post-Approval Market Access
Why European approval is only the first step – and how pricing, reimbursement, and launch planning differ from the US model
